Sign in

    Christopher Chen • Baird

    Christopher Chen is a Research Analyst at Baird specializing in the biotechnology and life sciences sector, with coverage of companies such as Larimar Therapeutics, Inc. Known for strong investigative skills and content management, he brings robust analytical expertise to his role. Chen joined Baird as a research analyst and has contributed to their acclaimed research team, although detailed performance metrics or rankings are not publicly disclosed. His professional credentials or FINRA registration specifics are not available based on current public records.

    Christopher Chen's questions to Mind Medicine (MindMed) Inc (MNMD) leadership

    Christopher Chen's questions to Mind Medicine (MindMed) Inc (MNMD) leadership • Q2 2025

    Question

    Christopher Chen from Baird asked to confirm the operational synergy of enrolling patients screened for GAD into the MDD trial if applicable, and requested more detail on the treatment visit, including provider presence and guardrails against psychotherapy.

    Answer

    CEO Robert Barrow confirmed the trial design allows for efficient crossover from GAD screening to MDD enrollment. CMO Dr. Daniel Karlin explained that during the treatment visit, a provider is present for monitoring and assistance, with explicit training and protocols in place to ensure they do not engage in psychotherapy while the patient focuses on their internal experience.

    Ask Fintool Equity Research AI